Comparing the Diagnostic Role of PET/MRI and of PET/CT Among Patients With Gastric Cancer
1 other identifier
observational
100
0 countries
N/A
Brief Summary
The results of PET/MRI and PET/CT in each recruited gastric cancer patients will be compared.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jan 2017
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 29, 2016
CompletedStudy Start
First participant enrolled
January 1, 2017
CompletedFirst Posted
Study publicly available on registry
January 10, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2018
CompletedJanuary 10, 2017
January 1, 2017
11 months
December 29, 2016
January 9, 2017
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
The results of the PET/MRI and PET/CT examination
Two experienced radiologists independently assess the TNM staging of gastric cancer using preoperative PET/MRI and PET/CT images
3 days
Secondary Outcomes (7)
Histopathological diagnosis
5 days
Results of CT/Endoscopic ultrasound(EUS) image
3 days
Numerical values of Standard uptake value(SUV)
3 days
Apparent Diffusion Coefficient(ADC)
3 days
The expression level of Receptor tyrosine-protein kinase erbB-2(HER2)
5 days
- +2 more secondary outcomes
Study Arms (1)
Gastric cancer
Each patient will perform a PET/MRI examination,and in the next day,a PET/CT.All the examinations are performed before the operation.
Interventions
The recruited patients will receive a PET/MRI examination to evaluation the stage and resectability of the cancer.
At the next day of PET/MRI examination,A PET/CT examination will be performed.
Eligibility Criteria
The cohort will recruit from patients diagnosed as gastric cancer and treated in the Department of general surgery.
You may qualify if:
- Histological diagnosis of gastric cancer
- No previous treatment history for gastric cancer
- Without complications of obstruction,bleeding and so on
- Without severe diabetes,the levels of blood glucose \<6.2 mmol/L .
- No cardiac pacemarker,never stimulator or other metal substitute materials in vivo.
You may not qualify if:
- With other neoplastic disease.
- Suffering acute inflammatory disease
- History of chemo-radiotherapy
- Suffering prostate hyperplasia,glaucoma
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Jianxin Cui, Doctor
the Chinese PLA General Hospital
- PRINCIPAL INVESTIGATOR
Yi Liu
the Chinese PLA General Hospital
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Director
Study Record Dates
First Submitted
December 29, 2016
First Posted
January 10, 2017
Study Start
January 1, 2017
Primary Completion
December 1, 2017
Study Completion
June 1, 2018
Last Updated
January 10, 2017
Record last verified: 2017-01
Data Sharing
- IPD Sharing
- Will not share